...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Cardiology >Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction
【24h】

Characteristics and Outcomes in Patients Presenting With COVID-19 and ST-Segment Elevation Myocardial Infarction

机译：Covid-19和ST段抬高心肌梗死患者的特征和结果

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There is limited information regarding clinical characteristics and outcomes of patients with SARS-CoV-2 (COVID-19) disease presenting with ST-segment elevation myocardial infarction (STEMI). In this multicenter retrospective study, we reviewed charts of patients admitted with symptomatic COVID-19 infection and STEMI to a total of 4 hospitals spanning Italy, Lithuania, Spain and Iraq from February 1, 2020 to April 15, 2020. A total of 78 patients were included in this study, 49 (63%) of whom were men, with a median age of 65 [58, 71] years, and high comorbidity burden. During hospitalization, 8 (10%) developed acute respiratory distress syndrome, and 14 (18%) required mechanical ventilation. 19 (24%) patients were treated with primary Percutaneous Coronary Intervention (PCI) and 59 (76%) were treated with fibrinolytic therapy. 13 (17%) patients required cardiac resuscitation, and 9 (11%) died. For the 19 patients treated with primary PCI, 8 (42%) required intubation and 8 (42%) required cardiac resuscitation; stent thrombosis occurred in 4 patients (21%). A total of 5 patients (26%) died during hospitalization. 50 (85%) of the 59 patients initially treated with fibrinolytic therapy had successful fibrinolysis. The median time to reperfusion was 27 minutes [20, 34]. Hemorrhagic stroke occurred in 5 patients (9%). Six patients (10%) required invasive mechanical ventilation; 5 (9%) required cardiac resuscitation, and 4 (7%) died. In conclusion, this is the largest case series to-date of COVID-19 positive patients presenting with STEMI and spans 4 countries. We found a high rate of stent thrombosis, indicating a possible need to adapt STEMI management for COVID-19 patients. (C) 2020 Elsevier Inc. All rights reserved.
机译：关于以ST段抬高心肌梗死（STEMI）为表现的SARS-CoV-2（COVID-19）疾病患者的临床特征和预后的信息有限。在这项2019冠状病毒疾病回顾性研究中，我们回顾了2020年2月1日至2020年4月15日期间，意大利、立陶宛、西班牙和伊拉克共有4所医院的症状性COVID-19感染和STEMI患者的病史。本研究共纳入78例患者，其中49例（63%）为男性，中位年龄为65岁[58,71]，共病负担高。住院期间，8人（10%）出现急性呼吸窘迫综合征，14人（18%）需要机械通气。19例（24%）患者接受了直接经皮冠状动脉介入治疗（PCI），59例（76%）患者接受了纤溶治疗。13例（17%）患者需要心脏复苏，9例（11%）死亡。在19例接受直接PCI治疗的患者中，8例（42%）需要插管，8例（42%）需要心脏复苏；支架血栓形成4例（21%）。共有5名患者（26%）在住院期间死亡。最初接受纤溶治疗的59名患者中有50名（85%）纤溶成功。再灌注的中位时间为27分钟[20,34]。出血性卒中5例（9%）。6名患者（10%）需要有创机械通气；5例（9%）需要心脏复苏，4例（7%）死亡。总之，这是2019冠状病毒疾病患者中最大的病例系列，其表现为STEMI和跨越4个国家。我们发现2019冠状病毒疾病的支架支架血栓形成率高，表明需要对STEMI进行COVID-19患者的治疗。（C） 2020爱思唯尔公司版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号